INTRODUCED BY: Medical Cannabis Task Force

SUBJECT: Report of the Medical Cannabis Task Force

Background and History of the Task Force and Medical Cannabis in Maryland

While MedChi continues to have no position on the effectiveness of medical cannabis, we understand some practitioners and patients want to use the product. MedChi has created a series of tools and resources for those physicians found here:

MedChi Tools for Cannabis Recommenders: https://www.medchi.org/medcan

MedChi and the Task force continue to work to educate physicians on the rules and regulations regarding this drug.

Background on Maryland Law Regarding Recommending Cannabis in Maryland

In accordance with Maryland law, in order to issue written certifications for medical cannabis to patients for treatment of a qualifying medical condition, practitioners must register as a “Certifying Provider” with the Maryland Medical Cannabis Commission.

Qualifying medical conditions include cachexia, anorexia, wasting syndrome, severe pain, severe nausea, seizures, severe or persistent muscle spasms, glaucoma, post-traumatic stress disorder, and chronic pain.

The requirements for issuing a written certification for medical cannabis are:

- A “bona fide provider-patient relationship” with the patient
- The patient’s condition must be severe
- Other medical treatments must have proven ineffective for the patient’s condition, and
- The symptoms must reasonably be expected to be relieved by the use of medical cannabis.

Maryland law defines a “bona fide relationship” as a treatment or counseling relationship between a provider and patient in which the provider reviews the patient’s relevant medical records, completes an in-person assessment of the patient’s medical history and current medical condition, creates and maintains medically standardized records, expects to monitor patient program, and takes any medically indicated action to follow up.
Once issued, a physician may amend or revoke a patient’s written certification on any medical grounds or if the patient no longer meets the physician’s inclusion criteria or the patient now meets the physician’s exclusion criteria. Examples of exclusion criteria include suspicion on the part of the provider that the patient is abusing cannabis or diverting cannabis to others.

Any physician with an active, unrestricted license in good standing with the Maryland Board of Physicians who is also actively registered to prescribe controlled substances in Maryland is eligible to register with the Maryland Medical Cannabis Commission.

**Legislative Cannabis Activity in the Last General Assembly Session**

**Dispensary Licenses**
The first major bill was Senate Bill 426 – Medical Cannabis – Regulation of Dispensaries, Growers, and Processors. This bill allows a person to have an interest (ownership, control of, or a management agreement) in no more than four dispensaries. The legislation maintained the requirement for only one license for both growers and processors.

**Advertising, Edibles, Academic Institutions, and Moratorium Extension**
The second major piece of legislation affecting the cannabis industry was House Bill 17 – Natalie M. LaPrade Medical Cannabis Commission – Processing and Dispensing Medical Cannabis. This came to be referred to as the “Omnibus Cannabis Bill” because it consolidated multiple pieces of cannabis-related legislation into one bill. The bill passed on the last day of Session. As passed, it is an emergency bill that makes numerous changes to the State’s medical cannabis program, including:

1. Authorizing an academic research representative (employee of an institution of higher education, a related medical facility, or an affiliated biomedical research firm) to register with the Natalie M. LaPrade Medical Cannabis Commission (Commission) to purchase medical cannabis for research purposes.
2. Requiring the Commission to allow licensed medical cannabis dispensaries and processors to sell “edible cannabis products.”

   - “Edible cannabis product” means a medical cannabis product intended for human consumption by oral ingestion, in whole or in part, including medical cannabis products that dissolve or disintegrate in the mouth. “Edible cannabis product” does not include any medical cannabis concentrate; medical cannabis–infused product, including an oil, a wax, an ointment, a salve, a tincture, a capsule, a suppository, a dermal patch, or a cartridge; or other dosage form that is recognized by the United States Pharmacopeia, the National Formulary, or the Food and Drug Administration and is approved by the Commission.
   - The Commission, in consultation with the Maryland Department of Health must adopt regulations, including but not limited to the packaging, labeling, marketing, and appearance of edible cannabis products, to ensure the safety of minors.
   - The Commission may also adopt regulations to require a processor to meet any additional
requirements that the Commission determines are necessary, including requiring a permit, for the processing of edible cannabis products.

(3) Increasing the length of time from two to three years a medical cannabis license holder must be actively engaged in the industry before selling or transferring ownership of the license.

(4) Adding the revocation of mandatory supervision, parole or probation to the legal protections for individuals participating in the State’s medical cannabis program.

(5) Restricting medical cannabis advertising as follows:

- All advertisements for medical cannabis, medical cannabis products, edible cannabis products, or medical cannabis–related services that make therapeutic or medical claims must:
  - Be supported by substantial clinical evidence or substantial clinical data; and
  - Include information on the most significant side effects or risks associated with the use of cannabis.
- An advertisement for a grower, a processor, a dispensary, an independent testing laboratory, a certifying provider, or a third–party vendor may not:
  - Make any statement that is false or misleading in any material way or is otherwise a violation of §§ 13–301 through 13–320 of the Commercial Law Article (abusive, deceptive, unfair trade practices).
  - Contain a design, an illustration, a picture, or a representation that:
    - encourages or represents the recreational use of cannabis;
    - targets or is attractive to minors, including a cartoon character, a mascot, or any other depiction that is commonly used to market products to minors;
    - displays the use of cannabis, including the consumption, smoking, or vaping of cannabis;
    - encourages or promotes cannabis for use as an intoxicant; or
    - is obscene.
- All advertising for medical cannabis, medical cannabis products, or edible cannabis products must include a statement that the product is for use only by a qualifying patient.
- Any website owned, managed, or operated by a certifying provider, dispensary, grower, or processor must employ a neutral age–screening mechanism that verifies that the user is at least 18 years of age, including by using an age–gate, age–screen, or age verification mechanism.
- An advertisement placed on social media or a mobile application must include a notification that:
  - A person must be at least 18 years old to view the content; and
  - Medical cannabis is for use by certified patients.
- These requirements do not apply to an advertisement placed on property owned or leased by a dispensary, grower, or processor.
- Any advertisement for medical cannabis, medical cannabis products, edible cannabis products, or medical cannabis–related services may not be placed within 500 feet of:
Pesticide Labeling
The third major bill was voted unfavorable by the Senate Judicial Proceedings Committee. Senate Bill 749 – Medical Cannabis – Pesticide Use – Labeling and Study would have required a licensed medical cannabis dispensary or a registered dispensary agent to ensure that all medical cannabis grown using a pesticide and medical cannabis products containing medical cannabis grown using a pesticide have a label affixed to the product at the time of sale stating that the medical cannabis was grown using pesticides.

Follow Up on House Resolutions
MedChi has diligently followed up on all cannabis related resolutions and communicated positions with regard to several House policies to the Commission and the Maryland General Assembly. Specifically, we have asked for cannabis recommendation information to be part of the Prescription Drug Monitoring Program (PDMP). We are working on a process to make cannabis recipients and dispensaries connected and required to share data with the PDMP through the State’s Health Information Exchange (CRISP).

MCTF Report 1-19 was accepted by the House of Delegates as an informational report at its meeting on November 2, 2019.